EUVIMEDEUVIMED entdecken
Crossref

Immune profiles and HIV reservoir in people switching to long‐acting cabotegravir/rilpivirine: Findings from a real‐life prospective study

Maria Mazzitelli iD, Maria Raffaella Petrara, Claudia Cozzolino, Lolita Sasset, Davide Leoni, Elena Ruffoni, Samuele Gardin, Beatrice Bragato, Angela Panese, Vincenzo Scaglione, Baldo Vincenzo, Anita De Rossi und 1 weitere

HIV Medicine · 2025

DOI: 10.1111/hiv.70030 ↗

Kurz gefasst

Fachartikel in der Zeitschrift HIV Medicine, 2025. Verfasst von Maria Mazzitelli und 12 weiteren Autor:innen. Beteiligte Einrichtung: Infectious and Tropical Diseases Unit, Padua University Hospital, Padova, Italy. Hauptthemen laut MEDLINE: HIV Infections, Rilpivirine, Anti-HIV Agents, Pyridones. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 31 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Data on the dynamics of HIV‐DNA and immune profiles under treatment with long‐acting cabotegravir and rilpivirine (LACR) are limited.

Methods

We prospectively enrolled people living with HIV who initiated LACR in our centre and assessed changes in HIV‐DNA levels (measured by digital droplet PCR), as well as immune activated, senescent, exhausted, and regulatory T and B cells (analysed by flow cytometry), in peripheral blood mononuclear cells (PBMC) from baseline (T0) to 48 weeks of treatment (T5). Bivariate analyses, one‐way repeated measures ANOVA and mixed ANOVA were conducted to assess differences in characteristics and biomarker changes over time between individuals switching to LACR from a dual (Group A) or triple (Group B) antiretroviral regimen.

Results

A total of 71 persons were included (77.5% males, median age of 48 years). Overall, HIV‐DNA levels exhibited a slight non‐significant decrease, whereas activated CD8 cells decreased significantly ( p < 0.001). Proportions of activated CD4 and regulatory T cells showed strong negative trends, but decreases did not reach statistical significance ( p = 0.002 and 0.005). The dynamics of these markers within the two subgroups mirrored those of the entire cohort, with some differences. At baseline, Group A tended to exhibit higher levels of HIV‐DNA (96 [31–160] vs. 41 [6–93] copies/10 6 PBMC, p = 0.088), and activated CD4 (% activated CD4 cells: 2.3 [1–2.9] vs. 1 [0.7–2], p = 0.154) and CD8 cells (% activated CD8 cells: 4.9 [2.2–5.8] vs. 2.2 [1.2–3.5], p = 0.023) than Group B. Over the 48‐week treatment period, HIV‐DNA levels decreased slightly in both groups, remaining higher in Group A. At the end of the 48‐week treatment period, the decrease of activated CD4 and CD8 cells was more pronounced in Group A than in Group B, ultimately reaching comparable levels between the two groups (% of activated CD4 cells: 0.9 [0.6–1.9] vs. 0.7 [0.6–1.1], p = 0.502): % of CD8 activated cells: (2 [1.3–2.5] vs. 1.6 [0.9–2.2], p = 0.278).

Conclusion

During the first year of treatment, LACR does not significantly impact the HIV reservoir. However, it may reduce immune activation, particularly in persons switching from a dual therapy regimen.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV InfectionsRilpivirineAnti-HIV AgentsPyridonesHumansMaleFemaleProspective StudiesMiddle AgedAdultDNA, ViralViral LoadHIV-1Diketopiperazines

Stichwörter der Autor:innen

HIVHIV‐DNAbiomarkersinflammationlong‐acting cabotegravir and rilpivirine

Substanzen

RilpivirineAnti-HIV AgentsDNA, ViralPyridonescabotegravirDiketopiperazines

Autor:innen und Institutionen

  • Infectious and Tropical Diseases Unit, Padua University Hospital, Padova, Italy.
  • Immunology and Molecular Oncology Diagnostics, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy.
  • Department of Cardiac, Thoracic, Vascular Sciences, and Public Health, University of Padua, Padua, Italy.
  • Oncology and Immunology Section, Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy.

ORCID-Profile: Maria Mazzitelli

Zitieren

APA

Mazzitelli, M., Petrara, M. R., Cozzolino, C., Sasset, L., Leoni, D., Ruffoni, E., Gardin, S., Bragato, B., Panese, A., Scaglione, V., Vincenzo, B., De Rossi, A., & Cattelan, A. M. (2025). Immune profiles and HIV reservoir in people switching to long‐acting cabotegravir/rilpivirine: Findings from a real‐life prospective study. HIV Medicine. https://doi.org/10.1111/hiv.70030

Vancouver

Mazzitelli M, Petrara MR, Cozzolino C, Sasset L, Leoni D, Ruffoni E, et al. Immune profiles and HIV reservoir in people switching to long‐acting cabotegravir/rilpivirine: Findings from a real‐life prospective study. HIV Medicine. 2025. doi:10.1111/hiv.70030

BibTeX
@article{Mazzitelli2025,
  author = {Mazzitelli, Maria and Petrara, Maria Raffaella and Cozzolino, Claudia and Sasset, Lolita and Leoni, Davide and Ruffoni, Elena and Gardin, Samuele and Bragato, Beatrice and Panese, Angela and Scaglione, Vincenzo and Vincenzo, Baldo and De Rossi, Anita and Cattelan, Anna Maria},
  title = {Immune profiles and HIV reservoir in people switching to long‐acting cabotegravir/rilpivirine: Findings from a real‐life prospective study},
  journal = {HIV Medicine},
  year = {2025},
  doi = {10.1111/hiv.70030}
}
Kostenlos starten →